Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a human IgG1 Fc tag at the C-terminus
The protein has a calculated MW of 40.3 kDa. The protein migrates as 50-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Rabbit CTLA-4, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human B7-1, mouse IgG2a Fc Tag, low endotoxin (Cat. No. B71-H52A4) at 5 μg/mL (100 μL/well)can bind Rabbit CTLA-4, Fc Tag (Cat. No. CT4-R5250) with a linear range of 0.1-0.8 ng/mL (QC tested).
Immobilized Human B7-2, His Tag (Cat. No. CD6-H5223) at 5 μg/mL (100 μL/well)can bind Rabbit CTLA-4, Fc Tag (Cat. No. CT4-R5250) with a linear range of 5-78 ng/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cadonilimab | AK-104; AK104 | Approved | Zhongshan Akeso Biopharma Co Ltd | 开坦尼 | Mainland China | Uterine Cervical Neoplasms | Kangfang Pharmaceutical Co Ltd | 2022-06-29 | Nasopharyngeal Carcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Esophageal Squamous Cell Carcinoma; DNA Repair-Deficiency Disorders; Urologic Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Microsatellite Instability; Solid tumours; Microsatellite instability-high cancer; Triple Negative Breast Neoplasms; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Vaginal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral | Details |
Ipilimumab | 10D1; MDX-CTLA-4; Anti-CTLA-4 Mab; BMS-734016; Mab-10D14; MDX-101; MDX-010 | Approved | Bristol-Myers Squibb Company | Yervoy, 逸沃 | United States | Melanoma | Bristol-Myers Squibb Company | 2011-03-25 | Primary Myelofibrosis; Brain metastases; Neoplasms, Gonadal Tissue; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Burkitt Lymphoma; Testicular Neoplasms; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Colorectal Neoplasms; Sezary Syndrome; Sarcoma; Neuroblastoma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Uterine Cervical Neoplasms; Endodermal Sinus Tumor; Leukemia, T-Cell; Leukemia, Large Granular Lymphocytic; Adenocarcinoma; Leukemia, Lymphocytic, Chronic, B-Cell; Mycosis Fungoides; Carcinoma, Hepatocellular; Prostatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Embryonal; Choriocarcinoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Intraocular Lymphoma; Lymphoma, T-Cell; Squamous Cell Carcinoma of Head and Neck; Carc | Details |
Tremelimumab | CP-675206; CP-675 | Approved | Pfizer Inc | IMJUDO | United States | Carcinoma, Hepatocellular | Astrazeneca Ab | 2022-10-21 | Urogenital Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Vulvar Neoplasms; Urethral Neoplasms; Colorectal Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Oropharyngeal Neoplasms; Ureteral Neoplasms; Peritoneal Neoplasms; Genital Neoplasms, Female; Carcinoma, Squamous Cell; Mouth Neoplasms; Prostatic Neoplasms; Gallbladder Neoplasms; Esophageal adenocarcinoma; Glioma; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Hepatitis C, Chronic; Adenocarcinoma; Uterine Cervical Neoplasms; Carcinoma, Endometrioid; Cystadenoma, Serous; Solid tumours; Head and Neck Neoplasms; Hematologic Neoplasms; Bone metastases; Kidney Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; HIV Infections; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Vaginal Neoplasms; Carcinoma; Liver Neoplasms; Cystadenocarcinoma, Serous; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Neopl | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CS-1002 | SHR-8068; CS-1002 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Stomach Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Botensilimab | AGEN-1181 | Phase 3 Clinical | Agenus Inc | Colonic Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Adenocarcinoma; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Esophageal adenocarcinoma; Colorectal Neoplasms; Prostatic Neoplasms; Microsatellite Instability; Solid tumours; Pancreatic Neoplasms; Neoplasms; Fibrolamellar hepatocellular carcinoma; Rectal Neoplasms; Carcinoma, Renal Cell; Hemangiosarcoma; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Neoplasms | Details |
Gotistobart | ONC-392; BNT316; BNT-316 | Phase 3 Clinical | Oncoimmune Inc | Carcinoma, Adenoid Cystic; Uterine Cervical Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Sarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Ovarian Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Salivary Gland Neoplasms; Pancreatic Neoplasms; Cystadenocarcinoma, Serous; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Anorectal disorders; Solid tumours; Head and Neck Neoplasms | Details |
Erfonrilimab | KN046; KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Thymoma; Esophageal Squamous Cell Carcinoma; Lymphoma; Solid tumours; Thymus Neoplasms; Breast Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Biliary Tract Neoplasms | Details |
Volrustomig | MEDI-5752; MEDI5752 | Phase 3 Clinical | Medimmune Llc | Biliary Tract Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Sarcoma; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
BCD-217 | BCD-217 | Phase 3 Clinical | Biocad | Melanoma | Details |
Ipilimumab biosimilar (Innovent Biologics) | IBI-310 | Phase 3 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Biliary Tract Neoplasms; Liver Neoplasms; Esophageal Neoplasms; Colonic Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Microsatellite Instability; Colorectal Neoplasms; Bile Duct Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
YH-001 | YH-001 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Liver Neoplasms; Solid tumours; Alopecia Areata; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
SI-B003 | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma | Details |
BMS-986288 | BMS-986288 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
Evalstotug | CAB-CTLA-4; BA-3071 | Phase 2 Clinical | Bioatla, Beigene Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Vudalimab | XmAb-20717; XmAb-717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Thymoma; Adenocarcinoma, Clear Cell; Cholangiocarcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Astrocytoma; Colorectal Neoplasms; Endometrial Neoplasms; Microsatellite instability-high cancer; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Hodgkin Disease; Adenoma, Acidophil; Colonic Neoplasms; Mesothelioma; Adnexal Diseases; Prostatic Neoplasms, Castration-Resistant | Details |
Recombinant anti-CTLA-4 human monoclonal antibody (Hualan Biological Engineering) | Phase 2 Clinical | Hualan Genetic Engineering Co Ltd | Melanoma | Details | |
Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Solid tumours; Liver Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital Of Shanghai | Pancreatic Neoplasms | Details | |
RP-2 | RP-2 | Phase 2 Clinical | Replimune Group Inc, Bristol-Myers Squibb Company | Neoplasms; Colorectal Neoplasms | Details |
Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
Quavonlimab | MK-1308; AK-107 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd, Merck Sharp & Dohme Corp | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Zalifrelimab | AGEN-1884; RebmAb-600; UGN-301 | Phase 2 Clinical | 4-Antibody, Ludwig Institute For Cancer Research | Solid tumours; Carcinoma; Hemangiosarcoma; Urinary Bladder Neoplasms; Sarcoma; Urologic Neoplasms; Carcinoma, Pancreatic Ductal; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BMS-986218 (Bristol-Myers Squibb) | BMS-986218 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours; Liver Neoplasms; Adrenal Gland Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Lung Neoplasms | Details |
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
KD-6001 | KD-6001 | Phase 2 Clinical | Shanghai Kanda Bio-Technology Co Ltd, Shanghai Celgen Bio-Pharmaceutical Co Ltd | Liver Neoplasms; Solid tumours; Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Porustobart | HBM-4003; HCAb 4003-2 | Phase 2 Clinical | Harbour Biomed | Solid tumours; Neoplasms; Neuroendocrine Tumors; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
JK-08 | JK-08 | Phase 2 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Small Cell Lung Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma; Carcinoma, Squamous Cell; Thyroid Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms | Details |
Sovipostobart | BMS-986249 | Phase 2 Clinical | Cytomx Therapeutics Inc | Neoplasms | Details |
GI-101 | SIM-323; SIM323; GI-101 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Vaginal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Urinary Bladder Neoplasms; Sarcoma; Vulvar Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
Firastotug | ADG-116 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
COYA-302 | COYA302; COYA 302; COYA-302 | Phase 2 Clinical | Coya Therapeutics Inc | Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
GI-102 | GI-102 | Phase 2 Clinical | GI Innovation Inc | Solid tumours; Neoplasm Metastasis | Details |
Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | Details | |
XTX-101 | XTX-101 | Phase 2 Clinical | Xilio Development Inc | Solid tumours | Details |
RP-3 | RP-3 | Phase 2 Clinical | Replimune Inc | Solid tumours; Liver Neoplasms; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
Muzastotug | ADG-126 | Phase 2 Clinical | Adagene Inc | Liver Neoplasms; Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | Details | |
JS-007 | JS007; JS-007 | Phase 2 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Pancreatic Neoplasms; Neoplasms; Lung Neoplasms; Melanoma | Details |
KN-044 | KN-044 | Phase 1 Clinical | Suzhou Alphamab Co Ltd | Solid tumours | Details |
Bavunalimab | XmAb-22841; XmAb-841 | Phase 1 Clinical | Xencor Inc | Cholangiocarcinoma; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Fallopian Tube Neoplasms; Penile Neoplasms; Endometrial Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Prostatic Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
ATOR-1015 | ADC-1015; ATOR-1015 | Phase 1 Clinical | Alligator Bioscience Ab | Solid tumours; Neoplasms | Details |
Anti-CTLA-4 monoclonal antibody (Regeneron) | REGN-4659 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Non-Small-Cell Lung | Details |
Ipilimumab biosimilar (Henlius) | HLX13 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Liver Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Renal Cell; Mesothelioma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma | Details |
Ipilimumab biosimilar (Mab-Venture/ShuangLu Pharmaceutical) | MV-049 | Phase 1 Clinical | Beijing Sl Pharmaceutical Co Ltd, Mab-Venture Biopharm Co Ltd | Solid tumours | Details |
SAL-008 | SAL-008 | Phase 1 Clinical | Xinlitai (Chengdu) Biological Technology Co Ltd | Neoplasms | Details |
GIGA-564 | GIGA-564 | Phase 1 Clinical | GigaGen Inc | Solid tumours; Neoplasms | Details |
A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | Details |
BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | Details |
MT-8421 | MT-8421; CTLA-4 ETB | Phase 1 Clinical | Molecular Templates Inc | Squamous Cell Carcinoma of Head and Neck; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Mesothelioma; Esophageal Squamous Cell Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Colorectal Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Fallopian Tube Neoplasms; Bile Duct Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Digestive System Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms; Anus Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Cystadenocarcinoma, Serous | Details |
KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | Details |
TG-6050 | TG-6050 | Phase 1 Clinical | Transgene Sa | Carcinoma, Non-Small-Cell Lung | Details |
IMM-27M | IMM27M; IMM-27M | Phase 1 Clinical | ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd | Solid tumours; Neoplasms; Pathologic Processes | Details |
TWP-102 | TWP-102 | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Neoplasms | Details |
SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
CD-200-AR-L | CD-200-AR-L; hP-1-A-8 | Phase 1 Clinical | University Of Minnesota, OX2 Therapeutics | Glioblastoma; Glioma | Details |
BAT-4706 | BAT-4706 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Melanoma | Details |
FPT-155 | CD80-Fc; FPT-155 | Phase 1 Clinical | Five Prime Therapeutics Inc | Solid tumours | Details |
B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
This web search service is supported by Google Inc.